Related references
Note: Only part of the references are listed.Dendritic cell biology and its role in tumor immunotherapy
Yingying Wang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)
Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer
James L. Gulley et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Cold Tumors: A Therapeutic Challenge for Immunotherapy
Paola Bonaventura et al.
FRONTIERS IN IMMUNOLOGY (2019)
Blocking PD-1/PD-L1 in Genitourinary Malignancies: To Immunity and Beyond
Matthew C. Dallos et al.
CANCER JOURNAL (2018)
Systematic Review of Immune Checkpoint Inhibition in Urological Cancers
Maud Rijnders et al.
EUROPEAN UROLOGY (2017)
Cancer Statistics, 2014
Rebecca Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2014)
Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer
Philip W. Kantoff et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer.
Philip W. Kantoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: Updated survival in the TAX 327 study
Dominik R. Berthold et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer
DP Petrylak et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer
S Halabi et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration
O Smaletz et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Share Paper
